Showing results (101-110 of 215) with videos related to
Sort By:
Pageof 22
Diseases of the Colon and Rectum|September 1, 1989
Multiple blood transfusions reduce the recurrence rate of Crohn's diseaseW R Peters, R D Fry, J W Fleshman, et al.Diseases of the Colon and Rectum|May 1, 1986
Clinical and operative experience with non-Caucasian patients with Crohn's diseaseC D Goldman, I J Kodner, R D Fry, et al.Neuroscience|October 31, 2009
Activation of extracellular signal-regulated kinases in social behavior circuits during resident-intruder aggression testsB C Trainor, K K Crean, W H D Fry, et al.Plant Disease|February 22, 2019
Population Dynamics of the Lance Nematode (Hoplolaimus galeatus) in Creeping BentgrassD M Settle, J D Fry, T C Todd, et al.International Journal of Colorectal Disease|March 20, 2015
Surveillance after neoadjuvant therapy in advanced rectal cancer with complete clinical response can have comparable outcomes to total mesorectal excisionRadhika K Smith, Robert D Fry, Najjia N Mahmoud, et al.Journal of Vascular and Interventional Radiology : JVIR|May 8, 2001
Treatment of type II endoleaks with OnyxM L Martin, B L Dolmatch, P D Fry, et al.Diseases of the Colon and Rectum|September 1, 1992
Accuracy of transrectal ultrasound in predicting pathologic stage of rectal cancer before and after preoperative radiation therapyJ W Fleshman, R J Myerson, R D Fry, et al.Behavioural Brain Research|January 12, 2010
Effects of photoperiod and experience on aggressive behavior in female California miceAndrea L Silva, William H D Fry, Colleen Sweeney, et al.BMC Evolutionary Biology|October 28, 2008
The genetic architecture of fitness in a seed beetle: assessing the potential for indirect genetic benefits of female choiceT Bilde, U Friberg, A A Maklakov, et al.Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|October 1, 1991
Phenotype and cytolytic activity of mouse tumor-bearer splenocytes and tumor-infiltrating lymphocytes from K-1735 melanoma metastases following anti-CD3, interleukin-2, and tumor necrosis factor-alpha combination immunotherapyS C Yang, K D Fry, E A Grimm, et al.Pageof 22